Cholesterol 7-alpha-monooxygenase (CYP7A1)

Cholesterol 7-alpha-monooxygenase, commonly known as CYP7A1, is the rate-limiting enzyme in the classic pathway of bile acid synthesis, where it catalyzes the conversion of cholesterol into 7-alpha-hydroxycholesterol. This enzymatic process serves as the primary route for the elimination of excess cholesterol from the liver and is essential for maintaining systemic cholesterol homeostasis. The expression of CYP7A1 is tightly regulated by complex feedback loops; for instance, bile acids returning to the liver activate the farnesoid X receptor (FXR), which triggers signaling pathways like FGF19-FGFR4 to repress the enzyme's activity. Genetic deficiency of CYP7A1 in humans is associated with hypercholesterolemia, increased LDL levels, and a higher risk of premature gallstones and atherosclerosis. Pharmacological modulation of the enzyme is a key therapeutic strategy: bile acid sequestrants and FGFR4 inhibitors are used to induce its expression and enhance cholesterol clearance, while FXR agonists repress its activity to prevent toxic bile acid accumulation in cholestatic liver diseases. Monitoring of CYP7A1 activity is clinically performed using the serum biomarker 7-alpha-hydroxy-4-cholesten-3-one (C4), which reflects the rate of bile acid production.

Other names

Cholesterol 7-alpha-hydroxylaseCytochrome P450 7A1CYP7CP7ACYPVIICytochrome P450 family 7 subfamily A member 1

Modulation of enzyme expression and activity through the interruption of negative feedback loops (e.g., bile acid sequestration) or the targeting of regulatory nuclear receptors and signaling pathways (FXR/FGF19/FGFR4) to influence cholesterol catabolism and bile acid production.